GlobeNewswire Inc | Dec 22, 2021 09:25AM EST

December 22, 2021

BRYAN, Texas, Dec. 22, 2021 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA:IBIO) (iBio or the Company),a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-basedFastPharmingManufacturing System,todayannounced that it has adjourned its 2021 Annual Meeting of Shareholders (the Annual Meeting) with respect to Proposals 4 and 5.

The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. iBio subsequently received additional votes FOR the proposals, as well as support from a number of shareholders who changed their against votes. Given that voting is still trending in favor of these proposals, the Company has adjourned the reconvened Annual Meeting to provide its shareholders additional time to vote. The Annual Meeting will resume with respect to Proposal 4 and 5 at 9:00 a.m. Eastern time on January 31, 2022 and can be accessed at www.virtualshareholdermeeting.com/IBIO2021.

If you have already voted your shares FOR Proposals 4 and 5, we thank you. If you did not yet vote, abstained, or voted against, we kindly ask you to vote, or to reconsider your vote.

For additional informationon the Proposals,please see our Shareholder Vote FAQ.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. ItsFastPharmingSystemcombines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, antigens, and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Companys wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services for advanced recombinant protein design. For more information, visitwww.ibioinc.com.

Contact:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580skilmer@ibioinc.com